Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON20968
NL-OMON20968
Recruiting
Not Applicable

A randomised, placebo controlled double blind study to assess the efficacy of a probiotic dairy product containing Lactobacillus casei Shirota on symptoms, visceroperception and inflammation in Irritable Bowel Syndrome.

Yakult Honsha Co. Ltd.1-19, 1 Chome, Higashi-ShinbashiMinato-ku 105-8660Tokyo JAPANContact person: Mr OosawaContact person in Europe: Dr S Kudo or Dr J Zhao, science managerScience department of Yakult Europe B.V.Yakult Europe B.V.Schutsluisweg 11332 EN ALMEREThe Netherlands0031(0)3652113000 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIrritable Bowel Syndrome (IBS) = Prikkelbare Darm Syndroom (PDS).probiotics = probioticacytokine profiles = cytokine profielenvisceroperception = visceroperceptielowgrade inflammation = laaggradige ontsteking

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Irritable Bowel Syndrome (IBS) = Prikkelbare Darm Syndroom (PDS).probiotics = probioticacytokine profiles = cytokine profielenvisceroperception = visceroperceptielowgrade inflammation = laaggradige ontsteking
Sponsor
Yakult Honsha Co. Ltd.1-19, 1 Chome, Higashi-ShinbashiMinato-ku 105-8660Tokyo JAPANContact person: Mr OosawaContact person in Europe: Dr S Kudo or Dr J Zhao, science managerScience department of Yakult Europe B.V.Yakult Europe B.V.Schutsluisweg 11332 EN ALMEREThe Netherlands0031(0)365211300
Enrollment
60
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Yakult Honsha Co. Ltd.1-19, 1 Chome, Higashi-ShinbashiMinato-ku 105-8660Tokyo JAPANContact person: Mr OosawaContact person in Europe: Dr S Kudo or Dr J Zhao, science managerScience department of Yakult Europe B.V.Yakult Europe B.V.Schutsluisweg 11332 EN ALMEREThe Netherlands0031(0)365211300

Eligibility Criteria

Inclusion Criteria

  • •Patients will be included when:
  • •1\. Diagnosed with IBS according to the ROME II criteria.

Exclusion Criteria

  • •1\. Patients who have had gastrointestinal surgery resulting in gastric resection, small intestinal or colonic resection.
  • •2\. Patients who are allergic to milk protein

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A study to investigate efficacy, safety and tolerability of a medicin (risperidone) in treatment of aggression in children and adolescents.Conduct DisorderChildrenAdolescentsAggressionRisperidoneEfficacySafetyTolerabilityAgressie KinderenAdolescentenRisperidonMedicatieEffectiviteitVeiligheid
NL-OMON21876Prof J.K. Buitelaar, Radboud University Medical Centre, Nijmegen, The Netherlands264
Recruiting
Not Applicable
The FCATFibromyalgia
NL-OMON28585eiden University Medical Center (LUMC)40
Recruiting
Not Applicable
The LCAT studyow back pain
NL-OMON26947eiden University Medical Center (LUMC)40
Not yet recruiting
Not Applicable
A double-blind, placebo controlled, randomized study comparing the effects of amitriptyline on dyspeptic symptoms in patients with functional dyspepsia.functional dyspepsia
NL-OMON25161Academic Medical Center (AMC) Amsterdam, Department gastroenterology220
Recruiting
Not Applicable
A Randomized placebo controlled double blind clinical trial comparing selenium and pentoxifylline in patients with mild Graves' orbitopathy. EUGOGO study BMild Graves' orbitopathy
NL-OMON24865Prof. dr. W.M. WiersingaDept. of Endocrinology and MetabolismAcademic Medical CenterMeibergdreef 91105 AZ AmsterdamT: +31 20 5666071F: +31 20 6917682e-mail: w.m.wiersinga@amc.uva.nl156